Panbela Therapeutics, Inc. (PBLA)
OTCMKTS · Delayed Price · Currency is USD
0.0111
0.00 (0.00%)
At close: Jun 4, 2026
Panbela Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Secured a $12 million strategic loan, supporting clinical progress in late-stage cancer trials and extending cash runway into Q1 2025. Key programs, including the ASPIRE and PACES trials, are advancing on schedule, with significant milestones expected in 2025.
-
ASPIRE phase III trial enrollment is ahead of schedule, with interim analysis now expected in early 2025 due to prolonged patient survival. Cash remains low, but recent asset monetization and a $1.5M loan support ongoing clinical programs.